Expert review of cardiovascular therapy · 2026
Effects of mineralocorticoid receptor antagonists on cardiometabolic profile and liver health in individuals with increased cardiometabolic risk: a systematic review and meta-analysis of randomized controlled trials.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dias João, Leite Ana Rita, Godinho Tiago, Correia-Chaves Joana, Borges-Canha Marta, Leite-Moreira Adelino, Neves João Sérgio
Аннотация
INTRODUCTION: Recent studies link overactivation of mineralocorticoid receptors to insulin resistance, inflammation, and metabolic dysfunction-associated steatotic liver disease. We aimed to assess the effects of mineralocorticoid receptor antagonists (MRAs) on liver steatosis, fibrosis, inflammation, and cardiometabolic risk.
METHODS: We conducted a systematic review and meta-analysis including placebo-controlled randomized controlled trials (RCTs) assessing MRAs' effects. A random-effects meta-analysis assessed MRAs effects on anthropometry, lipid profile, inflammatory parameters, and glucose metabolism. Outcomes were presented as mean differences (MD) with 95% confidence intervals (95% CI). Twenty-six studies were included and seventeen were meta-analyzed. MRAs studied included spironolactone, eplerenone, canrenone, apararenone, and finerenone. Most studies included participants with diabetes, metabolic syndrome, obesity, heart failure, or hypertension.
RESULTS: In the meta-analysis, we found a mild but significant decrease in body weight (MD = -1.27, 95% CI [-2.54, -0.01]) and a trend for higher HbA1c (MD = 0.13, 95% CI [-0.01, 0.27]) with MRAs. There was a trend toward a decrease in C-reactive protein levels (MD = -0.99, 95% CI [-2.22, 0.24]) with MRAs. RCTs on liver function and structure showed no differences compared to placebo.
CONCLUSIONS: MRAs appear to have a mild impact on metabolic and inflammatory parameters in patients with increased cardiometabolic risk. However, more RCTs on MRAs' cardiometabolic impact are needed.
REGISTRATION: This study was registered with PROSPERO (CRD42025632202).
METHODS: We conducted a systematic review and meta-analysis including placebo-controlled randomized controlled trials (RCTs) assessing MRAs' effects. A random-effects meta-analysis assessed MRAs effects on anthropometry, lipid profile, inflammatory parameters, and glucose metabolism. Outcomes were presented as mean differences (MD) with 95% confidence intervals (95% CI). Twenty-six studies were included and seventeen were meta-analyzed. MRAs studied included spironolactone, eplerenone, canrenone, apararenone, and finerenone. Most studies included participants with diabetes, metabolic syndrome, obesity, heart failure, or hypertension.
RESULTS: In the meta-analysis, we found a mild but significant decrease in body weight (MD = -1.27, 95% CI [-2.54, -0.01]) and a trend for higher HbA1c (MD = 0.13, 95% CI [-0.01, 0.27]) with MRAs. There was a trend toward a decrease in C-reactive protein levels (MD = -0.99, 95% CI [-2.22, 0.24]) with MRAs. RCTs on liver function and structure showed no differences compared to placebo.
CONCLUSIONS: MRAs appear to have a mild impact on metabolic and inflammatory parameters in patients with increased cardiometabolic risk. However, more RCTs on MRAs' cardiometabolic impact are needed.
REGISTRATION: This study was registered with PROSPERO (CRD42025632202).